Zanubrutinib

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Ovarian cancer, SLS, Survival, Lymphoma, Fast track (FDA), PTCL, National Cancer Institute, CMC, Clinical trial, Committee, Research, NCI, European School, Bone marrow, AML, GPS, Pembrolizumab, Doctor of Science, Nivolumab, Safety, MRD, CDK9, BLA, Food, CR2, Zanubrutinib, Mesothelioma, BIW, MD, Completeness, WT1, FDA, DLBCL, IDMC, Therapeutic index, Type, Fast Track, Biomarker, BTK, Pharmaceutical industry

The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.

Key Points: 
  • The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
  • The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
  • The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.

Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 22, 2023
P.C, Lymphocytosis, Chronic lymphocytic leukemia, VSAT, BeiGene, Food, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Sale, Morning Star, Patent, AbbVie, News, Ibrutinib, Communications satellite, Audit, Pharmaceutical industry, Viasat, Zanubrutinib

NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. (NASDAQ: VSAT) and BeiGene Ltd. (NASDAQ: BGNE).

Key Points: 
  • NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viasat, Inc. (NASDAQ: VSAT) and BeiGene Ltd. (NASDAQ: BGNE).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 17, 2023
P.C, Lymphocytosis, ARVL, Depression, TD, Chronic lymphocytic leukemia, Wells, BeiGene, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Electric Bond and Share Company v. Securities and Exchange Commission, Sale, Morning Star, Arrival, American Society of Clinical Oncology, Acquisition, Patent, AbbVie, Security (finance), Society, News, Ibrutinib, Food, Cryptocurrency, Audit, Zanubrutinib, Coinbase

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental health conditions.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All

Retrieved on: 
Tuesday, July 11, 2023
D, IPSC, Hematology, Culture, Feedback, Cell therapy, Monash University, Cancer, Research, Multimedia, Cell, BTK, Science, Philosophy, Name, Hospital, Patient, Developed country, Quality control, Pharmaceutical industry, BeiGene, Tislelizumab, Zanubrutinib

With the inauguration of a new state-of-the-art cell therapy lab in early 2022, BeiGene is looking to broaden collaboration and expand capability in the field of anticancer cell therapy.

Key Points: 
  • With the inauguration of a new state-of-the-art cell therapy lab in early 2022, BeiGene is looking to broaden collaboration and expand capability in the field of anticancer cell therapy.
  • BeiGene only made its first foray into anticancer cell therapy in June 2021, via a collaboration agreement signed with Shoreline Biosciences, a California-based biotech company specializing in natural killer cell therapies.
  • Dr. Huang emphasized that BeiGene not only sought to develop effective anticancer cell therapies, but was also committed to making such treatments affordable and accessible to all patients in need.
  • However, to make cell therapies widely affordable, allogeneic cell therapy based on induced pluripotent stem cells (iPSC) was likely to be an important focus of research going forward.

Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 11, 2023
News, Defamation, P.C, FOX, Lymphocytosis, Fox, Chronic lymphocytic leukemia, BeiGene, ABBV, Food and Drug Administration, Fox News, Cancer, Pharmacyclics, Sale, Government, Morning Star, United States presidential election, Fox Corporation, FOXA, Patent, AbbVie, Algorithm, Dominion, Ibrutinib, Food, Dominion Voting Systems, Pharmaceutical industry, Zanubrutinib

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA).

Key Points: 
  • NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.
  • For more information on the BeiGene investigation go to: https://bespc.com/cases/BGNE
    In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued Fox for defamation.

Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 6, 2023
News, Defamation, P.C, FOX, Lymphocytosis, Chronic lymphocytic leukemia, Fox, BeiGene, ABBV, Food and Drug Administration, Fox News, Cancer, Pharmacyclics, Sale, Government, United States presidential election, Morning Star, Fox Corporation, FOXA, Patent, AbbVie, Algorithm, Dominion, Ibrutinib, Food, Dominion Voting Systems, Pharmaceutical industry, Zanubrutinib

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp. (NASDAQ: FOX, FOXA) and BeiGene Limited (NASDAQ: BGNE).

Key Points: 
  • NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp. (NASDAQ: FOX, FOXA) and BeiGene Limited (NASDAQ: BGNE).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued Fox for defamation.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE

Retrieved on: 
Saturday, July 1, 2023
Titan, Lymphocytosis, Chronic lymphocytic leukemia, BeiGene, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Sale, Morning Star, Patent, AbbVie, Advertising, News, I-Space (Chinese company), Ibrutinib, Food, Cryptocurrency, Zanubrutinib

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=17184 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=17184 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 1, 2023
News, Defamation, P.C, FOX, Lymphocytosis, Fox, Depression, Chronic lymphocytic leukemia, BeiGene, ABBV, Food and Drug Administration, Fox News, Cancer, EPAM Systems, Pharmacyclics, EPAM, Sale, Government, Morning Star, United States presidential election, Fox Corporation, American Society of Clinical Oncology, FOXA, Patent, AbbVie, Algorithm, Dominion, Society, NYSE, Ibrutinib, Food, Dominion Voting Systems, Cryptocurrency, Audit, Pharmaceutical industry, Zanubrutinib

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, EPAM's stock price fell $56.40 per share, or 21.72%, to close at $203.25 per share on June 5, 2023.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.
  • For more information on the BeiGene investigation go to: https://bespc.com/cases/BGNE
    In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued Fox for defamation.

BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, June 27, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Lymphocytosis, Chronic lymphocytic leukemia, Telephone, ABBV, Food and Drug Administration, Cancer, Jeanne Eagels, Pharmacyclics, Sale, Morning Star, Patent, AbbVie, News, Ibrutinib, Food, Pharmaceutical industry, BeiGene, Zanubrutinib

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE) on behalf of BeiGene stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE) on behalf of BeiGene stockholders.
  • Our investigation concerns whether BeiGene has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • The next day, BeiGene ADS’ declined by as much as $5.3, or 2.65%, in intraday trading.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE

Retrieved on: 
Sunday, June 25, 2023
Titan, Lymphocytosis, Chronic lymphocytic leukemia, BeiGene, ABBV, Food and Drug Administration, Cancer, Pharmacyclics, Sale, Morning Star, Patent, AbbVie, Advertising, News, I-Space (Chinese company), Ibrutinib, Food, Cryptocurrency, Zanubrutinib

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=17184 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.